Virbac Posts Strong Q1 2026 Growth on Supercharge Platforms

Event summary

Q1 2026 revenue reached €384m, up +7.7% at CERS vs Q1 2025 (+2.2% at actual rates due to currency headwinds)
Companion animal segment grew +9.9%, farm animal +8.4%; Supercharge platforms (excl. Thyronorm) rose ~+15%
North America led growth with +20.7% CERS, International region +9.1%, Europe +2.0%
Thyronorm acquisition contributed 1ppt to overall growth; 2026 guidance unchanged at 5.5%-7.5% revenue growth

The big picture

Virbac's Q1 2026 results highlight the effectiveness of its 'Growing Together' strategy, with balanced growth across companion and farm animal segments. The strong performance in North America and International markets underscores the company's ability to capitalize on high-unmet-need areas through its Supercharge platforms. However, competitive pressures in Pacific and global uncertainties pose challenges to maintaining this momentum.

What we're watching

Geographic Expansion: Whether Virbac can sustain North America's +20.7% growth amid CMO difficulties in farm animal segment.
Currency Risks: How significant currency headwinds will impact actual revenue growth for the remainder of 2026.
Integration Success: The pace at which Thyronorm acquisition contributes to Virbac's endocrinology leadership.